271 related articles for article (PubMed ID: 8383567)
21. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
22. Asthma and airway inflammation: potential anti-inflammatory activities of phosphodiesterase inhibitors.
Lagente V; Hichami A; Boichot E; Martins MA; Silva PM
Allerg Immunol (Paris); 1995 Feb; 27(2):34-9. PubMed ID: 7710653
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
[TBL] [Abstract][Full Text] [Related]
24. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
25. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase IV inhibitors synergistically potentiate relaxation induced by forskolin in guinea-pig trachea.
Tanizawa M; Watanabe T; Kume H; Yamaki K; Miyamoto K; Takagi K
Clin Exp Pharmacol Physiol; 1998 Feb; 25(2):114-9. PubMed ID: 9493499
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.
Bethke T; Meyer W; Schmitz W; Scholz H; Stein B; Thomas K; Wenzlaff H
Br J Pharmacol; 1992 Sep; 107(1):127-33. PubMed ID: 1384905
[TBL] [Abstract][Full Text] [Related]
28. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor.
Raeburn D; Underwood SL; Lewis SA; Woodman VR; Battram CH; Tomkinson A; Sharma S; Jordan R; Souness JE; Webber SE
Br J Pharmacol; 1994 Dec; 113(4):1423-31. PubMed ID: 7889300
[TBL] [Abstract][Full Text] [Related]
29. Potential use of selective phosphodiesterase inhibitors in the treatment of asthma.
Murray KJ; Eden RJ; England PJ; Dolan J; Grimsditch DC; Stutchbury CA; Patel B; Reeves ML; Worby A; Torphy TJ
Agents Actions Suppl; 1991; 34():27-46. PubMed ID: 1665307
[TBL] [Abstract][Full Text] [Related]
30. Effects of alkyl substituents of xanthine on phosphodiesterase isoenzymes.
Miyamoto K; Sakai R; Kurita M; Ohmae S; Sanae F; Sawanishi H; Hasegawa T; Takagi K
Biol Pharm Bull; 1995 Mar; 18(3):431-4. PubMed ID: 7550097
[TBL] [Abstract][Full Text] [Related]
31. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma.
Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G
J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728
[TBL] [Abstract][Full Text] [Related]
32. Selective tracheal relaxation and phosphodiesterase-IV inhibition by xanthine derivatives.
Miyamoto K; Kurita M; Ohmae S; Sakai R; Sanae F; Takagi K
Eur J Pharmacol; 1994 May; 267(3):317-22. PubMed ID: 8088370
[TBL] [Abstract][Full Text] [Related]
33. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
34. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
Turner NC; Lamb J; Worby A; Murray KJ
Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
[TBL] [Abstract][Full Text] [Related]
35. Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.
Turner NC; Dolan JS; Grimsditch D; Lamb J; Worby A; Murray KJ; Coates WJ; Warrington BH
Br J Pharmacol; 1994 Apr; 111(4):1198-204. PubMed ID: 8032606
[TBL] [Abstract][Full Text] [Related]
36. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram.
Kochetkova M; Burns FM; Souness JE
Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330
[TBL] [Abstract][Full Text] [Related]
37. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor.
Holbrook M; Gozzard N; James T; Higgs G; Hughes B
Br J Pharmacol; 1996 Jul; 118(5):1192-200. PubMed ID: 8818343
[TBL] [Abstract][Full Text] [Related]
39. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.
Torphy TJ; Undem BJ; Cieslinski LB; Luttmann MA; Reeves ML; Hay DW
J Pharmacol Exp Ther; 1993 Jun; 265(3):1213-23. PubMed ID: 8389856
[TBL] [Abstract][Full Text] [Related]
40. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.
Souness JE; Carter CM; Diocee BK; Hassall GA; Wood LJ; Turner NC
Biochem Pharmacol; 1991 Jul; 42(4):937-45. PubMed ID: 1651083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
